Microbot Medical Expands Global Patent Portfolio With New Approvals Across the U.S., Japan, China and Canada
Microbot Medical, a medical technology company developing and distributing the innovative LIBERTY Endovascular Robotic System, has announced several new patent approvals across the United States, Japan, China and Canada. The latest approvals strengthen the company’s global intellectual property portfolio as it continues to expand the commercial adoption of its LIBERTY System in the United States and prepares for potential growth in international markets.
The company’s intellectual property developments come as Microbot Medical continues to pursue a CE Mark for the LIBERTY System, an important step in its strategy to access markets in the European Union. By securing patent protection in multiple jurisdictions, the company aims to safeguard its technological innovations, support future commercialization opportunities and establish a stronger foundation for international growth.
Following the latest approvals, Microbot Medical holds a total of 44 issued patents and 49 pending patent applications across North America, Europe, Israel and Asia. This portfolio represents the company’s ongoing efforts to protect its proprietary technologies while developing a broader commercial presence for its robotic endovascular platform.
The new patent approvals reflect Microbot Medical’s strategy of building and maintaining a diverse intellectual property portfolio alongside its commercial and research and development activities. The company believes that protecting its technology is essential to preserving the value of its innovations and supporting future opportunities to expand its presence in the medical device market.
As healthcare providers increasingly explore advanced technologies to support minimally invasive procedures, robotic systems are attracting attention for their potential to improve procedural precision, support remote operation and reduce some of the physical demands associated with conventional techniques. Microbot Medical is positioning its LIBERTY System within this evolving market, with intellectual property protection forming an important part of its broader business strategy.
New Patent Approvals Strengthen International Protection
The latest patent approvals span four major markets: the United States, Japan, China and Canada. These jurisdictions represent important regions for medical technology innovation, intellectual property protection and potential commercial development.
For medical device companies, patents can play a significant role in protecting the technical features that differentiate their products. Intellectual property rights may help companies safeguard proprietary designs, technological approaches and other innovations against unauthorized use, subject to the scope and enforceability of the relevant patents.
Securing patents in multiple countries can also help businesses prepare for international commercialization. Medical device companies entering new markets must consider not only regulatory requirements and customer demand but also the legal frameworks governing their technologies.
Microbot Medical’s expanding patent portfolio is intended to support these objectives. By pursuing protection across North America, Europe and Asia, the company is working to establish a broader foundation for the commercialization of its robotic technologies.
The new approvals add to the company’s existing intellectual property holdings and demonstrate continued activity in protecting its innovations. With 44 issued patents and 49 pending applications, Microbot Medical has established a portfolio that spans several regions where it may seek future commercial opportunities.
However, patent approval and commercial market access are separate matters. Patents protect eligible intellectual property rights, while medical device sales and clinical use remain subject to applicable regulatory requirements in each jurisdiction. The company’s pursuit of a CE Mark therefore represents a distinct part of its European market strategy.
Together, intellectual property development, regulatory progress and commercial expansion form interconnected elements of Microbot Medical’s plans for the LIBERTY System.
Intellectual Property as a Foundation for Business Growth
Microbot Medical views its intellectual property portfolio as a strategic business asset that can support the company’s development and commercialization objectives.
For medical technology businesses, innovation alone may not be sufficient to establish a sustainable market position. Companies must also protect their technologies, demonstrate their value to potential customers and navigate the regulatory processes required to introduce products into new markets.
A well-developed patent portfolio can contribute to this process by helping protect a company’s proprietary innovations. It can also support discussions with potential commercial partners, distributors and other organizations interested in the technology, although the value of any particular patent depends on factors such as its scope, enforceability and commercial relevance.
Microbot Medical’s strategy combines intellectual property development with efforts to increase commercial adoption of the LIBERTY System. The company is continuing to build its U.S. commercial presence while pursuing opportunities in additional international markets.
The company believes that a strong patent estate is important to supporting future market expansion and potentially monetizing its technology. Intellectual property can contribute to commercialization through multiple routes, including direct product sales, strategic partnerships and licensing arrangements, where appropriate. The announcement does not specify any new licensing agreements or monetization transactions resulting from the latest patent approvals.
The growing portfolio nevertheless provides a framework for protecting the technology as the company continues to develop its business.
For emerging medical device companies, balancing innovation with commercial execution is particularly important. Research and development must continue to produce meaningful technical progress, while intellectual property strategies should be aligned with product development plans and anticipated market opportunities.
Microbot Medical’s latest patent approvals reflect this relationship between protecting innovation and preparing for broader market access.
Leadership Highlights Collaboration Across Research and Development
Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical, said the company’s commercial progress since the launch of LIBERTY is closely connected to its efforts to strengthen its intellectual property portfolio and develop the infrastructure needed to support wider market access.
“Our commercial growth since the launch of LIBERTY goes hand in hand with our strategy to enhance and strengthen our intellectual property portfolio while simultaneously building the global infrastructure needed to support broader market access for the LIBERTY System,” Garten said.
She also emphasized the importance of collaboration between the company’s research and development and business development teams.
According to Garten, the teams’ ongoing collaboration is contributing to the development of a robust and diverse intellectual property portfolio, which the company expects to expand significantly over the coming months. She noted that these developments align with Microbot Medical’s strategy for entering the European Union and other jurisdictions.
The comments highlight the role of cross-functional coordination in medical technology development. Research and development teams focus on advancing product technologies, while intellectual property professionals work to identify and protect potentially valuable innovations. Business development teams, meanwhile, assess commercial opportunities and relationships that may help bring products to additional markets.
When these functions work together, companies can align their innovation activities with longer-term business priorities. Patent planning can be integrated into product development, while commercial teams can help identify markets and applications where the technology may have potential.
For Microbot Medical, the collaboration is intended to strengthen the company’s ability to protect its innovations while preparing the LIBERTY System for broader commercial opportunities.
The company’s expectation that its intellectual property portfolio will continue to grow also indicates that patent development remains an ongoing part of its strategy rather than a one-time milestone.
LIBERTY System Targets Peripheral Endovascular Procedures
At the center of Microbot Medical’s commercialization strategy is the LIBERTY Endovascular Robotic System, which the company describes as the only U.S. Food and Drug Administration-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The system is designed to support precise navigation through blood vessels during peripheral endovascular interventions. These procedures involve accessing the vascular system to diagnose or treat conditions affecting blood vessels outside the heart and brain, depending on the procedure and clinical indication.
Endovascular techniques typically use instruments such as catheters and guidewires that are advanced through blood vessels to reach a target area. The ability to navigate these instruments accurately is an important part of procedural execution.
Robotic technologies are being developed to support clinicians in manipulating instruments and controlling their movement during selected procedures. Depending on the system and its approved use, robotic assistance may help provide controlled movement, improve the ergonomics of procedural work or support alternative approaches to operating instruments.
The LIBERTY System is designed for remote operation and single use. These characteristics distinguish its intended operating model from systems that rely on reusable robotic platforms or direct manual manipulation throughout a procedure.
Microbot Medical says the system is designed to support precise vascular navigation while aiming to reduce radiation exposure and physical strain. These are important considerations in endovascular environments, where clinicians may spend extended periods working with imaging guidance and specialized instruments.
Radiation exposure is a recognized occupational consideration in image-guided procedures. Depending on the procedure, equipment, protective measures and working practices, clinicians may be exposed to scattered radiation generated during imaging. Technologies that alter how clinicians interact with procedural equipment may offer potential ergonomic or radiation-related advantages, but the degree of benefit must be established through appropriate evidence and evaluated within the specific clinical setting.
Similarly, reducing physical strain is relevant to procedural teams who may spend long periods standing in fixed or demanding positions. Robotic systems designed to change how instruments are controlled may provide a different working arrangement, although actual benefits depend on system design, procedural workflow and clinical use.
The company’s stated design objectives therefore address both the technical demands of vascular navigation and aspects of the procedural environment.
Commercial Adoption and Regulatory Expansion
Microbot Medical is continuing to pursue commercial adoption of the LIBERTY System in the United States while preparing for potential expansion into international markets.
Commercial adoption of a medical device typically requires more than regulatory clearance. Healthcare providers may evaluate a product’s clinical suitability, ease of integration into existing workflows, training requirements, operational considerations and potential value to the organization.
Medical technology companies must also establish the infrastructure needed to support customers. This can include distribution arrangements, training, technical support, product availability and relationships with healthcare institutions.
Microbot Medical’s announcement connects its intellectual property efforts with the development of the global infrastructure required to support wider access to the LIBERTY System. This suggests that patent protection is one part of a broader commercialization effort involving market development and operational readiness.
The company’s pursuit of a CE Mark is another important component of its international strategy. A CE Mark indicates conformity with applicable European Union requirements for the relevant product category and regulatory pathway. For medical devices, the process involves demonstrating compliance with the requirements that apply to the device before it can be placed on the European market.
The announcement confirms that Microbot Medical is pursuing a CE Mark, but it does not state that the certification has been granted. The company’s future access to European markets will depend on completing the applicable regulatory process and meeting other relevant requirements.
The latest patent approvals in Japan, China and Canada likewise strengthen intellectual property protection in those markets but do not, by themselves, establish regulatory authorization or commercial availability there.
By addressing intellectual property and regulatory considerations in parallel, Microbot Medical is working toward a broader foundation for potential international growth.
The Role of Patents in Medical Robotics
Medical robotics is an area of technology development in which intellectual property can be particularly important. Robotic systems may combine mechanical components, instrument-control mechanisms, software, navigation approaches and other technical features. Depending on the innovation and applicable patent law, different elements may be eligible for patent protection.
For companies developing robotic medical devices, patent strategies can help protect technical advances made during research and development. They may also support investment in continued innovation by helping companies establish rights over inventions that distinguish their products.
International patent protection requires planning because patent rights are territorial. Protection granted in one country does not automatically provide equivalent rights in another. Companies seeking to operate globally may therefore pursue applications and approvals across multiple jurisdictions, subject to local laws and filing requirements.
Microbot Medical’s portfolio spans North America, Europe, Israel and Asia. The company’s latest approvals across the United States, Japan, China and Canada add to this international coverage.
Maintaining a portfolio of issued patents and pending applications also reflects the continuing nature of medical technology development. New product features, technical refinements and future innovations may create additional opportunities for intellectual property protection, depending on their novelty and other applicable criteria.
The company’s current total of 44 issued patents and 49 pending applications provides a measure of the scale of its patent activity. The number of patents alone, however, does not determine commercial success. Their significance depends on the technologies they cover, the markets in which they apply and how effectively the company converts its innovations into products and business opportunities.
For Microbot Medical, the strategic objective is to use intellectual property protection as part of a wider effort to support the LIBERTY System’s development and commercial growth.
Microbot Medical’s latest patent approvals represent a further step in its effort to strengthen the intellectual property protection surrounding its LIBERTY Endovascular Robotic System.
With 44 issued patents and 49 pending patent applications across North America, Europe, Israel and Asia, the company is continuing to build a portfolio intended to protect its innovations and support future commercial opportunities.
The approvals in the United States, Japan, China and Canada arrive as Microbot Medical works to expand U.S. adoption of LIBERTY and pursues a CE Mark as part of its plans for the European market. The company has also indicated that it expects its intellectual property portfolio to expand further in the coming months through continued collaboration between its research and development and business development teams.
The LIBERTY System remains central to these efforts. Designed as a single-use, remotely operated robotic platform for peripheral endovascular procedures, it aims to support precise vascular navigation while addressing concerns associated with radiation exposure and physical strain.
As the company progresses, its ability to translate technological innovation into commercial adoption will depend on several interconnected factors, including intellectual property protection, regulatory progress, customer engagement and the development of appropriate market infrastructure.
The latest patent approvals strengthen one part of that strategy by extending protection for Microbot Medical’s innovations across additional jurisdictions. Combined with its ongoing commercial activities and international regulatory efforts, the developments support the company’s broader objective of building a foundation for the future growth of the LIBERTY System.
While the new approvals do not independently guarantee regulatory clearance or commercial success in any market, they represent continued progress in the company’s stated effort to protect its technology and prepare for broader access to global medical device markets.
Source link: https://ir.microbotmedical.com/
